Description

IGF-1 LR3 2 mg — Sterling Knight Pharmaceuticals

Catégorie : Peptide / Growth Factor Research Compound
Marque : Sterling Knight Pharmaceuticals
Strength: 2 mg (lyophilised)
Form: Sterile peptide vial for reconstitution
Packing: 1 × vial
Origin: United Kingdom
Prix : €39

Research Use: For laboratory, analytical and in-vitro work only. Not for human or veterinary use.

🧬 What Is IGF-1 LR3?

IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified recombinant analog of human IGF-1 engineered for increased bioavailability et reduced binding to IGF-binding proteins (IGFBPs).

It contains:

• A substitution of Arg → Glu at position 3
• A 13-amino-acid N-terminal extension
• Total length: 83 amino acids
• Molecular weight: ~9.1 kDa

These changes preserve IGF-1 receptor agonism while greatly improving stability and potency relative to native IGF-1.

🔬 Key Research Highlights

1. Reduced IGFBP Binding

Native IGF-1 binds strongly to IGFBPs, limiting activity in cell-culture systems. IGF-1 LR3 shows significantly lower IGFBP affinity, resulting in:

• Higher free fraction
• Greater receptor availability
• Enhanced potency in vitro

2. Extended Half-Life

Literature reports half-life ranges from 20–30 hours to 56–72 hours, depending on experimental matrix and method. This enables more sustained IGF-1 pathway activation in culture models.

3. Proven Utility in Cell-Culture Systems

• Improves survival in low-serum and serum-free environments
• Promotes proliferation in IGF-dependent lines
• Often more effective than insulin or IGF-1

4. Anti-Doping Relevance

IGF-1 and analogs, including LR3, are prohibited under WADA S2 (Peptide hormones, growth factors, related substances and mimetics).

📚 Research Applications

• IGF-1 receptor signalling models
• Protein synthesis and cell-growth assays
• PK/PD comparison of IGF-1 analog stability
• Method development for LC-MS/MS anti-doping detection
• Cell-culture optimisation in reduced-serum environments

⚠️ Potential Risks & Class-Based Considerations

IGF-axis activation influences glucose handling, mitogenic pathways and cellular proliferation. Risks depend on model, concentration and exposure duration.

• May alter glucose uptake and insulin signalling
• May stimulate mitogenic/anti-apoptotic pathways
• Listed as a prohibited peptide under WADA S2

Handle as a bioactive peptide using appropriate PPE, SDS documentation and institutional biosafety protocols.

🛑 Compliance & Legal Notice

• FOR RESEARCH USE ONLY – Not for human consumption
• Not a medicine, supplement, or veterinary preparation
• Not intended for performance enhancement
• Must be used only by qualified personnel under laboratory SOPs
• WADA Category: S2 – Peptide hormones, growth factors, and mimetics

📊 Technical Data Table

Research chemical — not for human or veterinary use.